Poly[adenosine diphosphate (ADP)-ribose] polymerases (PARPs) are a family of enzymes that modulate diverse biological processes through covalent transfer of ADP-ribose from the oxidized form of nicotinamide adenine dinucleotide (NAD + ) onto substrate proteins. Here we report a robust NAD + analog-sensitive approach for PARPs, which allows PARP-specific ADP-ribosylation of substrates that is suitable for subsequent coppercatalyzed azide-alkyne cycloaddition reactions. Using this approach, we mapped hundreds of sites of ADP-ribosylation for PARPs 1, 2, and 3 across the proteome, as well as thousands of PARP-1-mediated ADP-ribosylation sites across the genome. We found that PARP-1 ADP-ribosylates and inhibits negative elongation factor (NELF), a protein complex that regulates promoter-proximal pausing by RNA polymerase II (Pol II). Depletion or inhibition of PARP-1 or mutation of the ADP-ribosylation sites on NELF-E promotes Pol II pausing, providing a clear functional link between PARP-1, ADP-ribosylation, and NELF. This analog-sensitive approach should be broadly applicable across the PARP family and has the potential to illuminate the ADP-ribosylated proteome and the molecular mechanisms used by individual PARPs to mediate their responses to cellular signals.
A denosine diphosphate (ADP)-ribosylation of proteins is an important modulator of cellular processes, from the regulation of chromatin and transcription to protein translation and stability (1) . Most of the 17 poly(ADP-ribose) polymerase (PARP) family members encoded in the human genome are enzymes with either mono-or poly(ADP-ribosyl) transferase activities, which covalently link ADPribose derived from the oxidized form of nicotinamide adenine dinucleotide (NAD + ) to their target proteins, primarily at glutamate, aspartate, and lysine residues (2). PARPs 1, 2, and 3, collectively referred to as the DNA-dependent PARPs, are a group of nuclear proteins with DNA-dependent mono-(PARP-3) or poly-(PARPs 1 and 2) ADPribosyl transferase activities involved in DNA repair, chromosome maintenance, chromatin regulation, and gene expression (2, 3) . Previous studies using immune-based enrichment, various affinity resins, or protein microarrays to identify the targets of ADP-ribosylation lacked specificity for individual PARP family members (4) . A recent chemical genetics approach targeting a conserved residue in the nicotinamide binding site of the PARP catalytic domain was a technological advance but unfortunately ablated the poly(ADP-ribosyl) transferase activity of PARP enzymes, while preserving mono(ADP-ribosyl) transferase activity (5, 6) . A single chemical genetic approach that preserves the natural mono-and poly(ADP-ribosyl) transferase activities of PARP enzymes and is broadly applicable across the PARP family should be of great utility.
An analog-sensitive PARP (asPARP) approach targeting the adenine moiety of NAD + Our previous studies indicated that the adenine moiety of NAD + is a useful target for chemical modification to alter the catalytic activity and chemistry of PARP family members (7) . In this regard, we developed an adenine-focused, NAD + analog-sensitive approach for PARPs that preserves their poly(ADP-ribosyl) transferase activity ( Fig. 1A and fig. S1A ) and is capable of identifying the specific targets of individual PARP family members. Analog sensitivity is achieved by mutation of a large "gatekeeper" amino acid in the active site of a protein to a smaller residue, creating a pocket that fits a bulky R group on an engineered substrate, whereas interaction of the bulky R group with the wild-type (WT) enzyme would have been sterically blocked (8) . We initially focused on PARP-1, an abundant and ubiquitously expressed PARP protein in metazoans. To identify a gatekeeper residue in PARP-1, we changed 10 large residues buried within the active site and facing the adenine ring of NAD + to glycine or alanine on the basis of a molecular model (Fig. 1A and figs. S1B and S2). We selected the eight position of the adenine ring of NAD + as the site for R group addition because its modification precludes ADP-ribosylation with WT PARP-1 (wtPARP-1) or other PARPs (7), a feature critical to the analog-sensitive approach.
We then synthesized a library of 11 NAD + analogs, each with a different R group at position eight, from 8-methylamino-NAD + to 8-benzylamino-NAD + (Fig. 1B) . In a screen of the 20 PARP-1 mutants versus the 11 NAD + analogs, we identified two different gatekeeper residues, L 877 and I 895 (9) , whose mutation to alanine results in analogsensitive activity in a PARP-1 automodification assay ( Fig. 1C and figs. S1C and S3). Critically, both of these residues are buried within the active site of the enzyme; thus, their mutation is unlikely to affect protein-protein interactions that might influence substrate selectivity. Although L 877 and I 895 are separated by 18 amino acids in the PARP-1 linear sequence, they are adjacent to one another and proximal to the eight position of the adenine ring in three-dimensional (3D) space (Fig. 1D) . These results support our molecular model of PARP-1 interactions with NAD + (figs. S1B and S2), as well as the structural basis for our asPARP approach.
To extend the utility of our asPARP approach, we functionalized the R group of 8-butylthio-NAD + (NAD + analog 6 in Fig. 1B ) with an alkyne moiety to generate 8-Bu(3-yne)T-NAD + ( Fig. 2A) . 8-Bu(3-yne)T-NAD + is an NAD + analog with a single bifunctional R group at position 8, which facilitates asPARP-selective ADP-ribosylation. The R group also allows incorporation of alkynes into the posttranslationally modified substrates, for subsequent use in azide-alkyne cycloaddition ("click" chemistry) reactions to label or purify the PARP targets (Fig. 2B) (Fig. 2C  and fig. S5, A and B) . The ability to transfer this analog-sensitive activity to the other PARPs by mutation of the conserved gatekeeper residue (Fig. 2C and fig. S5 , C to G) suggests broad utility of this approach across the PARP family, for both mono-and poly(ADP-ribosyl) transferases.
Identification of site-specific nuclear substrates of PARPs 1, 2, and 3
We used the asPARP approach to identify sitespecific ADP-ribosylation of glutamate and aspartate residues for nuclear substrates of PARPs 1, 2, and 3 (10). We incubated purified recombinant asPARPs 1, 2, or 3 with HeLa cell nuclear extract in the presence of 8-Bu(3-yne)T-NAD + , which resulted in PARP-specific labeling of extract proteins (Fig. 3A) . We then "clicked" the 8-Bu(3-yne) T-ADP-ribose-labeled proteins to azide-agarose, which led to their covalent attachment to the agarose resin, allowing extensive washing with denaturants, strong detergents, and organic solvents. We performed trypsin-based peptide identification of the ADP-ribosylated proteins by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (protein ID), washed extensively again, and eluted the ADP-ribosylated peptides using hydroxylamine to identify the sites of ADPribosylation by LC-MS/MS (site ID) (10) (Fig. 3B ). This approach revealed distinct and overlapping sites of PARP-1-, PARP-2-, and PARP-3-mediated ADP-ribosylation (Fig. 3C and fig. S6A ). Ontological analyses of the target proteins revealed enrichment of terms related to transcription and DNA repair-consistent with the known biology of PARPs 1, 2, and 3-as well as additional terms, suggesting previously unknown functions (Fig. 3D  and fig. S6B ).
Motif analyses at the sites of PARP-1-, PARP-2-, and PARP-3-mediated ADP-ribosylation indicate some similarities in sequence preference among the three PARPs (e.g., glutamate residue proximal to the site of modification) but point out differences as well ( fig. S6C ). The sites of PARP-1-, PARP-2-, and PARP-3-mediated ADP-ribosylation that we identified herein partially overlapped and were more numerous than sites of ADPribosylation identified using other approaches (fig. S7), with excellent agreement for the specific sites of ADP-ribosylation in common targets when compared to a previous cell-based bulk ADPribosylation assay (10) (Fig. 3E) . We also observed considerable overlap with an asPARP-1 data set that we generated from intact mouse embryonic fibroblast (MEF) nuclei ( fig. S8 ). Collectively, these results show that our asPARP approach robustly and faithfully identifies sites of ADP-ribosylation mediated by a specific PARP family member.
Negative elongation factor (NELF) is ADP-ribosylated in a positive transcription elongation factor (P-TEFb)-dependent manner Previous reports implicating the Drosophila melanogaster homolog of PARP-1 as a key modulator of RNA polymerase II (Pol II) pause release at heat shock loci (11, 12) , together with the identification of NELF-A and -E as ADPribosylated proteins ( Fig. 4A and fig. S6B ), led us to explore whether PARP-1 activity and ADPribosylation of the NELF complex might play a role in the control of transcription elongation. The negative elongation factor complex (NELF-A, -B, -C or -D, and -E) functions to restrict transcriptional elongation and stimulate promoter-proximal pausing by Pol II (13) . Immunoaffinity purification of NELF from mammalian cells expressing FLAG epitope-tagged NELF-E demonstrated that PARP-1 interacts with the NELF complex (Fig. 4B) and that NELF-E and NELF-A are ADP-ribosylated in mammalian cells (Fig. 4C) . Mutation of the four NELF-E glutamate residues identified in our proteomic screen (E122, E151, E172, and E374) (Fig. 4A ) to glutamines, a structurally similar residue refractory to ADP-ribosylation, resulted in a substantial reduction in NELF-E modification by PARP-1 (Fig.  4D) . Finally, using an electrophoretic mobility shift assay with a model NELF-E-interacting RNA [i.e., HIV trans-activation response element (TAR)], we found that ADP-ribosylation of NELF-E ablates its ability to bind RNA, a function necessary for the establishment paused Pol II (14) (Fig. 4E and  fig. S9 ). We found that phosphorylation sites (Fig.  4F ) and, to a lesser extent, sites of other posttranslational modifications ( fig. S10A ) are frequently located at or near ADP-ribosylation sites across the proteome. This suggests a broad role for ADP-ribosylation as a modulator at hubs of regulatory activity, as well as a more specific regulatory role for ADP-ribosylation (and PARPs) in cooperation with phosphorylation (and kinases) across the proteome. In fact, using a PARP inhibitor (PARPi) (i.e., PJ34) and a cyclin-dependent kinase 9 (CDK9) inhibitor (i.e., flavopiridol), we observed that ADP-ribosylation of NELF-E in mammalian cells is dependent on phosphorylation by CDK9/P-TEFb (Fig. 4G) , a kinase that phosphorylates Pol II, DSIF, and NELF-E (15). Furthermore, both inhibitors reduced the extent of serine-2 phosphorylation (Ser2P) in the Cterminal domain heptapeptide repeat of the Pol II RPB1 subunit in cells ( fig. S10B ). Because elevated Ser2P is associated with actively elongating Pol II (15), these results indicate a reduction in elongating Pol II upon inhibition of PARP-1 and CDK9. Interestingly, a 7-nucleotide oligomer amino acid sequence (RSRSRDR) enriched in targets of PARP-1 ( fig. S10C) is located within the previously identified phosphorylation target site for P-TEFb in NELF-E, near a cluster of PARP-1-mediated ADP-ribosylation sites (Fig. 4A) . Together, these results highlight the functional links between PARP-1-mediated ADP-ribosylation and transcription-related phosphorylation.
Identifying sites of PARP-1-mediated ADP-ribosylation across the genome
Although recent genomic approaches have facilitated the detection of sites of ADP-ribosylation genome-wide in the context of DNA damage (16), they have not allowed unambiguous assignment of genomic ADP-ribosylation events to a specific PARP family member in unstimulated cells. To unambiguously define sites of PARP-1-mediated ADP-ribosylation across the genome, we developed an assay, which we call "Click-ChIP-seq" (click chemistry-based chromatin isolation and precipitation with deep sequencing), using the asPARP-1 approach in nuclei. We and sheared the chromatin by sonication, finally subjecting the material to an assay analogous to chromatin immunoprecipitation ( Fig. 5A  and fig. S11C ). A quantitative polymerase chain reaction-based assay of the enriched genomic DNA revealed asPARP-1-specific ADP-ribosylation at gene promoters in nuclei isolated from MEFs ( fig. S11D ). Click-ChIP-seq revealed robust enrichment of PARP-1-mediated ADP-ribosylation at the promoters of transcriptionally active genes, which were defined by an enrichment of histone H3 lysine-4 trimethylation (H3K4me3, a mark of active promoters, from ChIP-seq) and actively transcribing Pol II [from global run-on sequencing (GRO-seq)] (Fig. 5B) . This assay also revealed genomic loci with significant peaks of PARP-1 lacking enrichment of PARP-1-mediated ADP-ribosylation located in regions of repressed chromatin ( fig.   S12 ), which are difficult to discern in the absence of the specificity provided by the asPARP approach. Genome-wide correlation analyses between PARP-1-mediated ADP-ribosylation and a variety of other histone modifications and chromatin or transcription-related factors revealed strong clustering, as well as positive correlations with PARP-1 (correlation coefficient r = 0.606) and NELF-B (r = 0.754) (Fig. 5C ). Heat-map representations of the genomic data highlight the relationships at gene promoters among PARP-1-mediated ADP-ribosylation; Pol II accumulation; and H3K4me3, NELF-B, and PARP-1 enrichment (Fig. 5D and fig. S13A ). PARP-1-mediated ADPribosylation and CDK9 occupancy at promoters strongly correlated with low levels of Pol II pausing ( fig. S13B ). These results suggest that PARP-1-mediated ADP-ribosylation may act in a manner similar to CDK9/P-TEFb-mediated phosphorylation to promote the release of paused Pol II into productive elongation.
Role of PARP-1-mediated ADP-ribosylation of NELF in the release of paused Pol II To determine the role of PARP-1 in the release of paused Pol II, we performed GRO-seq in MCF-7 breast cancer cells to monitor the effects of short hairpin RNA (shRNA)-mediated PARP-1 knockdown or treatment with the PARPi PJ34 on Pol II pausing. GRO-seq is a genomic assay that reveals the location of transcriptionally engaged RNA polymerases globally (17) . We observed an accumulation of reads in the peaks of paused Pol II upon PARP-1 knockdown or treatment with PARPi [compared with an untreated luciferase knockdown control (Luc)] at gene promoters ( fig. S14 ). This effect was evident genome-wide ( Fig. 6A) , with a clear increase in global Pol II pausing indices upon PARP-1 depletion or inhibition (Fig. 6B) . At active promoters with a significant accumulation of GRO-seq reads in the paused Pol II peak upon PARP-1 knockdown, we observed decreased GRO-seq reads in the gene bodies ( fig. S15, see panel B for the gene body effects), which suggests that PARP-1 activity is necessary to achieve an efficient release of Pol II into productive elongation.
We showed that a large fraction of PARP-1-regulated genes (determined by PARP-1 knockdown) are also regulated by P-TEFb [determined by treatment with 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB)] and NELF (determined by NELF knockdown), with respect to expression (by RNA-seq; fig. S16, A and B) and Pol II pausing (by Pol II ChIP-seq; fig. S16C ). In addition, we found that the viral NELF inhibitor HDAg-S (18) reverses the inhibitory effects of both PARP-1 knockdown and DRB treatment on Pol II pausing, as determined from a ChIP-seq-based "Pol II pausing efficacy" assay (i.e., promoter proximal Pol II enrichment divided by NELF-E enrichment) (Fig.  6C and figs. S17 and S18). Finally, we showed that a NELF-E ADP-ribosylation site mutant (Mut) produces a NELF complex that is resistant to the inhibitory effects of PARP-1 and is a more potent inducer of Pol II pausing than the NELF complex containing WT NELF-E, in spite of lower cellular expression levels (Fig. 6C and figs. S18 and S19) . Collectively, our data point to a functional link between CDK9-mediated phosphorylation, PARP-1-mediated ADP-ribosylation, and NELF-mediated Pol II pausing ( fig. S20 ). Our results indicate that PARP-1-dependent ADP-ribosylation of NELF-E reinforces P-TEFb-mediated Pol II pause release and productive elongation for a subset of NELFregulated genes, especially those with elevated NELF and Pol II loading, as well as H3K4me3 enrichment ( fig. S21 ). Finally, these mechanisms are functional even at promoters where PARP-1 serves noncatalytic functions, such as the expulsion of the linker histone H1 from nucleosomes (19) (fig. S22 ).
Conclusions and perspectives
PARP proteins have gained considerable attention as therapeutic targets for the treatment of cancers and other diseases (20) , although the broader biology of the PARP family remains largely unexplored. Understanding the biology of PARP proteins requires comprehension of the protein substrates that they modify. In this regard, we have developed an asPARP approach that preserves the natural mono-and poly(ADP-ribosyl) transferase activities of PARP enzymes, which can be coupled with protein mass spectrometry to identify the targets of specific PARP family members. We have also repurposed this asPARP technology for use in genomic assays to identify the genome-wide distribution of ADP-ribosylation events catalyzed by a specific PARP protein. Our studies focusing on NELF illustrate how an integrated approach based on asPARP technology can further the exploration of the biological functions for ADP-ribosylation. Our asPARP approach, which uses a conserved residue in the PARP catalytic domain, should be broadly applicable across the PARP family. This technique will facilitate the rapid, robust, and systematic identification of the molecular targets and mechanisms of action of the entire PARP family, with the potential to transform our understanding of PARP protein functions in physiology and disease. ; t test).
